REVIEW Sitagliptin is an orally available hypoglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-inhibiting drug is to be used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus. It is for use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.
REFERENCES
[1]
Sorbera, L. A.; Castaner, J. MK-0431: agent for type 2 diabetes and dipeptidyl-peptidase IV (CD26) inhibitor. Drugs of the Future. (2005) 30(4): 337-343.
[2]
Bardsley, Joan K.; Ratner, Robert E.Sitagliptin: an oral agent for glucose control Expert Review of Endocrinology & Metabolism (2008), 3(6), 691-697.
[3]
Dhillon, Sohita. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. (2010) 70(4): 489-512.
[4]
Edmondson, Scott D.; Fisher, Michael H.; Kim, Dooseop; MacCoss, Malcolm; Parmee, Emma R.; Weber, Ann E.; Xu, Jinyou Preparation of beta-amino tetrahydroimidazo[1,2-a]pyrazines and tetrahydrotrioazolo[4,3-a]pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes PCT Int. Appl. (2003), WO 2003004498 A1 20030116.
All products are stocked and shipped from San Francisco Bay Area, California, USA.
⚠️
All products are for research and development use only, not for any other uses, and must be handled by technically-qualified persons.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.
Add to Favorites 
Delete from Favorites 
